Who Are the Core Customers of 23andMe Company?

Proactive health consumers (largely Gen X and Millennials) drive growth: in 2025 this cohort accounted for the fastest-growing revenue segment as 23andMe expanded health reports and clinical pathways for chronic disease risk management such as Type 2 diabetes and hereditary cancer risk.

The Weight Management and Metabolic Health segment became strategic after GLP-1 clinical program integration; customers seek medically supervised, genetics-informed weight loss solutions and pharmacogenomic guidance-this segment elevated average revenue per user in 2025.

23andMe serves a mixed base: direct-to-consumer genetics customers for ancestry and health reports, plus institutional clients-pharmaceutical researchers-who access de-identified data from roughly 80 percent of customers who opt into research, powering large-scale genomic studies and partnerships.

In 2025 the Proactive Health Consumer and Weight Management cohorts were most commercially important as health-product attach rates and subscription services grew; clinical programs and pharma collaborations increased health-focused revenue share versus pure ancestry sales.

The United States generates the vast majority of 23andMe target audience revenue; in fiscal 2025 U.S. retail and direct sales accounted for roughly ~80% of total revenue, concentrated among adults aged 30-55 with higher income and education who prioritize preventative medicine and quantified-self tools.

Outside the U.S., demand is meaningful in Canada, the U.K., and Australia among ancestry DNA test buyers and genealogy enthusiasts; specialty verticals include clinicians using consumer results for family matching and research partners engaging direct-to-consumer genetics customers.

23andMe sees its highest-value demand through its direct-to-consumer digital platform, which drives subscription conversions to 23andMe+ and higher lifetime value; in 2025 direct channel gross margin and ARPU were notably higher than third-party retail.

By 2026 a fast-growing vertical is employer-sponsored wellness programs, where companies integrate genetic screening and weight-management reports to curb long-term insurance costs; pilot programs and corporate enrollments contributed a measurable new revenue stream in 2025-2026.

23andMe targets 23andMe customers and direct-to-consumer genetics customers by adding GLP-1 prescriptions and personalized primary care to move beyond ancestry DNA test buyers into health-focused genetic testing consumers; this attracts clinicians and health-seeking users while reaching new demographics through telehealth partnerships and pharmacy channels.

The company keeps 23andMe core customers engaged by tying new services to each user's DNA insights so ancestry fans and health-report seekers see clear, personalized value; ongoing health reports, family-matching features, and data-driven care paths preserve loyalty despite broader offerings.

Repeat demand comes from users converting to subscription-style care: genetics-led medication management and primary care raise customer lifetime value by creating recurring visits and prescriptions, increasing ecosystem stickiness for health-focused genetic testing consumers.

The main growth driver in 2025/2026 is proving superior genetics-led clinical outcomes; expanding into medical services targets higher lifetime revenue but faces higher customer acquisition costs-management signaled mixed results in early 2026 while monthly active patient conversion rates and retention metrics remain the key KPIs (2025 guidance cited recurring-revenue focus).